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Stubbe J, Madsen K, Nielsen FT, Bonde RK, Skøtt O, Jensen
BL. Postnatal adrenalectomy impairs urinary concentrating ability by
increased COX-2 and leads to renal medullary injury. Am J Physiol
Renal Physiol 293: F780–F789, 2007. First published June 20, 2007;
doi:10.1152/ajprenal.00193.2007.—We hypothesized that aldosterone
promotes development of the renal medulla in the postnatal period and
that cyclooxygenase-2 (COX-2) activity contributes to renal dysfunc-
tion after impaired aldosterone signaling. To test these hypotheses, rat
pups underwent either sham operation or adrenalectomy at postnatal
day 10. Adrenalectomized rats were divided into no steroid substitu-
tion (ADX), corticosterone replacement (ADX-C), and corticosterone
and DOCA substitution (ADX-CD) groups that received subcutane-
ous pellets with steroids. Without replacement, pups failed to thrive
and exhibited impaired urinary-concentrating ability. The renal me-
dulla was significantly smaller, and the medullary interstitial osmola-
lity was lower in the ADX group, whereas COX-2 and PGE2 tissue
levels were significantly elevated compared with levels shown in
sham animals. Substitution with DOCA and corticosterone corrected
these changes, whereas corticosterone replacement alone improved
survival but not weight gain and urinary-concentrating ability. Ad-
ministration of a COX-2 inhibitor to ADX rats (parecoxib, 5
mg kg1 day1, days 17–20) increased weight gain, urinary-concen-
trating ability, and papillary osmolality. After fluid deprivation, pare-
coxib attenuated weight loss and the increase in plasma Na concen-
tration and osmolality. It is concluded that mineralocorticoid is re-
quired for normal postnatal development of the renal medulla. COX-2
contributes to impaired urine-concentrating ability, NaCl loss, and extra-
cellular volume depletion in postnatal mineralocorticoid deficiency.
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DISTURBED FORMATION OF NEPHRONS during critical “windows” of
kidney development may be a predisposing factor for later
development of hypertension (3, 25). Nephron formation
ceases in the 36th wk of gestation in humans; however, in mice
and rats, induction of new nephrons proceeds 6–7 days after
birth (24). After nephron formation is complete, the renal
medulla is structurally and functionally immature. Loops of
Henle undergo considerable elongation to achieve the adult
conformation during the second and third postnatal weeks (in
rats) and during the first year of life (in humans), which
coincides with a marked increase of urinary-concentrating
ability (23). Loop growth takes place through mitotic activity
in thick ascending limbs and apoptotic remodeling in thin
limbs (4, 10). Subtle changes in medullary differentiation in
late stages of kidney development might alter long-term blood
pressure homeostasis despite a normal number of nephrons.
In rats, plasma glucocorticoid exhibits a developmental
nadir in the second postnatal week (9). Exposure to elevated
glucocorticoid in this period leads to hypertension in the adult
rat (21) and inhibits proliferation of the loop of Henle and the
kidney outer medulla (27). Little is known about factors that
initiate and maintain proliferation of loop cells at the outer
medulla-cortex junction. Pharmacological and genetic ap-
proaches employed to inhibit or delete components of the
renin-angiotensin-aldosterone system in the postnatal period
have consistently shown a range of abnormalities with dimin-
ished kidney growth, decreased ability to concentrate urine,
and pathological changes of the kidney medulla (6, 7, 14, 18,
20, 29, 30). In some of these experimental models, plasma
aldosterone is suppressed (29) and mice deficient in aldoste-
rone synthase (CYP11B2/) share several phenotypic char-
acteristics with kidneys from animals with interrupted ANG II
signaling (14). These observations imply a point of conver-
gence at the aldosterone-mineralocorticoid receptor (MR) path-
way for renal phenotypic alterations. It is not known whether
aldosterone is necessary for proliferation or apoptotic remod-
eling within the renal medulla and at which time during
postnatal development such sensitivity is present. Mineralocor-
ticoid might exert direct effects on the loop epithelium or
influence proliferation and growth indirectly through effects on
Na homeostasis. In this context, renal prostanoids appear
particularly relevant. Mineralocorticoid suppresses cortical cy-
clooxygenase-2 (COX-2) expression in developing and adult
kidney, whereas administration of AT1-receptor blockers and
MR antagonists stimulate renal COX-2 in the postnatal period
(26, 31, 32). Intrarenal COX-2 is elevated and promotes NaCl
wasting in NaCl-loosing tubulopathies (11, 19, 28). Whether
enhanced COX-2 activity contributes to renal dysfunction in
conditions with impaired postnatal mineralocorticoid signal-
ing has not previously been analyzed. We hypothesized that
1) aldosterone promotes renal medullary development in the
late postnatal phase after nephrogenesis by stimulating tu-
bular cell proliferation and remodeling and that 2) aldoste-
rone promotes development of urinary-concentrating ability
by indirect effects on COX-2 activity.
These hypotheses were tested in rat pups subjected to
adrenalectomy in the postnatal developmental “window,”
during which medullary proliferation peaks and nephron
formation is complete [between postnatal days 10 and 20
(P10 –P20)]. Pups were given differential replacement ther-
apy by chronic implantation of pellets that contained gluco-
and mineralocorticoid. In addition, short-term intervention
with a COX-2 blocker was used to elucidate the role of
COX-2 for impaired concentrating ability in adrenalecto-
mized rats.
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MATERIALS AND METHODS
Animal Surgery and Protocols
All procedures conformed to the Danish national guidelines for the
care and handling of animals and the published guidelines from the
National Institutes of Health. The Danish Animal Experiments In-
spectorate under the Department of Justice approved all experimental
procedures that involved the use of animals (no. 2003/561-761).
Female Sprague-Dawley rats had free access to standard pathogen-
free rat chow (Altromin-1310, Lage, Germany) (2 g/kg Na, 5 g/kg
Cl) and tap water. In the first 24 h after birth, litters were reduced to
10 to ensure equal feeding with five males and females in each litter,
if possible. The dams and pups were kept at a 12:12-h light-dark
cycle. At P10, pups were anesthetized with ketamine (25 mg/kg) and
xylazine (5 mg/kg), and bilateral adrenalectomy (ADX) was per-
formed through two lumbodorsal incisions. After surgery, rats were
divided into four groups: 1) sham group, which underwent a surgical
protocol without removal of adrenals [a pellet (50 mg cholesterol) was
inserted in the subcutis]; 2) ADX group, which did not have cortico-
steroid substitution and where a 50-mg pure cholesterol pellet was
inserted. In pilot experiments, most pups in this group died before
P20. Therefore, we adopted a protocol shown to sustain survival in
MR/ mice where pups were injected subcutaneously with isotonic
NaCl in an amount corresponding to urinary Na losses (2). The final
two groups were as follows: 3) ADX with corticosterone replacement
only (ADX-C), which had a pellet (50 mg) with 12.5% corticosterone
inserted in the subcutis; and 4) ADX with corticosterone and miner-
alocorticoid (DOCA) substitution (ADX-CD), which had a pellet (50
mg) with 12.5% corticosterone and 12.5% DOCA inserted. Pellets
were manufactured as described by Meyer et al. (15) for adult rats and
reduced from a 100-mg to a 50-mg size to adjust for different body
sizes and to maintain corticosterone at a level characteristic for the
second postnatal week in the rat (9). Pellets were “sterilized” by
heating for 2 h at 105°C. Pellets were stored at 4°C for a maximum
of 2 wk.
Experimental Series
Series 1. Spot urine was collected at day 20 from the four exper-
imental groups, and mixed trunk blood was sampled in EDTA-coated
or heparin-coated vials after decapitation. Kidneys were dissected in
outer medulla-cortex and inner medulla, snap frozen in liquid nitro-
gen, and stored at 80°C.
Series 2. To determine urinary-concentrating ability, the dam was
removed from the pups between P19 and P20 for 20 h. Spot urine was
collected at decapitation, and mixed trunk blood was sampled. Kid-
neys were dissected in outer medulla-cortex and inner medulla and
then frozen in liquid nitrogen and stored at 80°C.
Series 3. Pups from the four groups were anesthetized at P20 as
described above. Kidneys were fixed by systemic perfusion through
the left cardiac ventricle with 4% phosphate-buffered paraformalde-
hyde for 4 min. Coronal tissue blocks were processed for immuno-
histochemistry as described (27).
Series 4. Four litters were adrenalectomized at P10 and only
supplemented with isotonic NaCl injections. Pups were given subcu-
taneous injections of a COX-2-selective antagonist (parecoxib; Dy-
nastat; Merck), at 5 mg kg1 day1 divided in two daily doses (2.5
g/g in 5 l/g) from P17 to P20. The pups were then fluid deprived
for 20 h. Spot urine was collected, and pups were decapitated. Plasma,
urine, and kidneys were sampled. Inner medulla and cortex-outer
medulla were dissected out and rapidly frozen.
Plasma and Tissue Electrolyte Concentrations
In initial experiments, papillas were homogenized in pure water
and then centrifuged 10 min at 13.000 g, and supernatants were used
for measurements. In subsequent experiments, osmolytes were quan-
titatively extracted as described (27). Osmolality was analyzed by
freeze-point depression (Osmomat 030-D, Gonotec, Bie & Berntsen).
Na and K concentrations were determined in plasma and renal
medullary interstitial fluid by flame photometry (model IL 943;
Instrumentation Laboratory, Lexington, MA). Urea was determined
kinetically as the amount of NADH consumed over time measured
spectrometrically (UV) after hydrolysis of urea by urase and the
formation of L-glutamate by glutamate dehydrogenase (ABX Pentra
Urea CP, ABX Diagnostics).
Hormone Analyses
Plasma aldosterone was measured in all pups from series 1, 2, and
4 as a control of complete removal of all adrenal tissue with a
commercial kit (COAT-A-COUNT; Diagnostic Products, Los Ange-
les, CA). The detection limit was 13.0 pg/ml, and the intra-assay
coefficient of variation was 4%. Plasma total corticosterone was
measured with the radioimmunoassay kit from Amersham’s Biotrak
series, using 125I-labeled corticosterone as a tracer. Plasma renin
concentration was analyzed as described (22). For tissue PGE2,
samples were homogenized as described for Western blotting, and 250
l of homogenate were acidified with 18 l of 50% formic acid.
Samples were extracted with 1 ml ethylacetate-hexane (70/30) by
Table 1. Characteristics of adrenalectomized and sham-operated rat pups at P20
Sham ADX ADX-C ADX-CD
Body weight P20, g 44.41 (n15) 35.91*(n8) 37.82.4† (n8) 44.23.7§a (n11)
Kidney weight, mg 45616 (n8) 36828*(n4) 36539† (n4) 4929§a (n6)
Kidney-to-body weight ratio, mg/g 9.90.1 (n8) 9.90.4 (n4) 9.40.1 (n4) 10.50.2a (n6)
Urine osmolality, mosmol/kgH2O 786129 (n10) 50345 (n8) 668123 (n6) 758115 (n8)
Plasma [Na], mM 134.61.5 (n6) 1282.6 (n4) 118.75.8 (n4) 139.35.5a (n6)
Plasma renin concentration, 105 GU/ml 6346 (n13) 1886953*(n6) 1,539750† (n5) 2.90.4§a (n7)
Plasma corticosterone, ng/ml 13730 (n11) 2610*(n5) 299 (n4) 255‡ (n8)
Fluid deprivation
Plasma [Na], mM 1391 (n6) 1273*(n6) 1292† (n6) 1554‡§a (n6)
Urinary osmolality, mosmol/kgH2O 1,698177 (n7) 47445*(n5) 860128† (n5) 1,476138§a (n7)
Papillary osmolality, mosmol/kgH2O, 56262 (n7) 31121*(n8) 39229† (n9) 49337§ (n10)
Papillary [Na], mM 763 (n7) 443*(n8) 484† (n9) 776§a (n10)
Values are means  SE. P20, postnatal day 20; [Na], Na concentration. GU, Goldblatt units. Adrenalectomy or sham surgery was performed at postnatal
day 10 (P10), and rat pups were divided into the following groups: Sham (no steroid substitution, NaCl supplementation), ADX (adrenalectomy with no steroid
substitution), ADX-C (adrenalectomy with corticosterone replacement), and ADX-CD (adrenalectomy with corticosterone and DOCA substitution). In the
fluid-deprivation protocol, pups were removed from the dam for 20–22 h. Data sets that were normally or log-normally distributed were evaluated statistically
by ANOVA followed by Tukey-Kramer multiple comparisons test. Data that were not normally distributed were evaluated by Kruskal-Wallis test followed by
Dunn’s multiple comparison test. P  0.05: *Sham vs. ADX; †Sham vs. ADX-C; ‡Sham vs. ADX-CD; §ADX vs. ADX-CD; aADX-C vs. ADX-CD.
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vortexing and subsequent centrifugation. The supernatants were vac-
uum dried and dissolved in 250 l of assay buffer. PGE2 was
determined by ELISA (Assay Designs).
Messenger RNA Analyses
Isolation of RNA and quantitative RT-PCR were performed as
described previously (27). A standard curve was constructed by
plotting threshold cycle against serial dilutions of linearized plasmids.
A subset of quantitative RT-PCR data sets was validated by subse-
quent ribonuclease protection assay as previously described (27).
Western Blotting
Tissue samples were homogenized in buffer as previously de-
scribed in detail (27). Protein concentration determination, gel elec-
trophoresis, electroblotting, and chemiluminescence detection were
done as previously described (27). Densitometry was evaluated by
Fig. 1. A: kidneys from the 4 experimental groups of pups were sectioned in the frontal plane. Pups (n 5 in each group) were substituted with cholesterol pellets
with no steroid [with sham operation (sham) or with adrenalectomy (ADX)], with 12.5% corticosterone (ADX-C), and with 12.5% corticosterone and 12.5%
DOCA (ADX-CD). B: compound pictures show low-power magnification micrographs of histological sections of pup kidneys from the 4 experimental groups
at postnatal day 20 (P20). Sections are stained with hematoxylin. Bars  500 m. C: micrographs show histological sections of kidneys from the 4 experimental
groups at P20. Sections are reacted with a proliferating cell nuclear antigen (PCNA)-specific antibody by histochemical reaction. D, left: result of Western blotting
experiment using whole kidney homogenate from sham and nonsubstituted ADX rat pups at P20 reacted with a specific antibody for PCNA. D, right: result of
densitometric evaluation of the film. OD, optical density.
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QuantityOne software (BioRad). Primary antibodies used were as
follows: COX-2 (1:2,000, M-19, Santa Cruz); Na-K-ATPase 1
(1:2,000, Upstate); proliferating cell nuclear antigen (PCNA; 1:2,000,
Santa Cruz); and sodium-potassium-2-chloride cotransporter (NKCC2;
1:2,000, Chemicon).
Morphometry and Immunohistochemistry
Fixation and paraffin embedding for immunochemistry was as
described previously (27). Primary antibodies for immunohistochem-
istry were as follows: COX-2 (1:1,000, M-19, Santa Cruz); NKCC2
(1:1,000, Chemicon); the potassium channel ROMK (1:500, Alomone
Labs); Na-K-ATPase 1 (1:100, Upstate); PCNA (1:100, Santa
Cruz); and Tamm-Horsfall glycoprotein (1:200, Biotrend). For mor-
phometric analysis, coronal sections through the tip of papilla were
labeled for Tamm-Horsfall glycoprotein to allow precise delineation
of kidney outer medulla and inner medulla. Juxtamedullary glomeruli
defined the cortical-outer medulla junction in morphometric analysis.
Measurement of kidney dimensions was done with Image Tool
version 3.0 (National Institutes of Health) as described (27).
Statistics
If data were not normally distributed, they were log-transformed
and tested for normality. Statistical significance between several
groups was evaluated by one-way ANOVA followed by the Tukey-
Kramer multiple comparisons test. Unpaired Student’s t-test was used
when two groups were evaluated. If data were not normally distrib-
uted or variance was not homogenous, a nonparametric Mann-Whit-
ney test was used to test for significant differences between two
groups, and differences between more than two groups were estimated
by the Kruskal-Wallis test followed by Dunn’s multiple comparisons
test. P values 0.05 were considered significant. Arithmetic means
are shown as  SE; for log-transformed data, geometric means are
shown. All calculations were performed with GraphPad Prism InStat
software (version 3.0; GraphPad, San Diego, CA).
RESULTS
Effect of Adrenalectomy on Body and Kidney Growth and
Plasma Hormone and Electrolyte Concentrations
Plasma aldosterone concentration was 87  22 pg/ml in
sham-operated rats at P20 (n  13) and was below the
detection limit after adrenalectomy in all included rats (not
shown; assay limit of 11 pg/ml, n  7–9 animals in each
group). In control pups not subjected to surgery, plasma cor-
ticosterone increased 10 times between P10 and weaning at
P20 (13.4  1.3 ng/ml vs. 128.7  28 ng/ml; n  5 in both
groups), which was not different from plasma corticosterone in
sham-operated pups at P20 (137  30 ng/ml; n  13). In the
ADX group that received no steroid replacement, corticoste-
rone was detectable in plasma at P20, but the developmental
surge was prevented (Table 1). In ADX-C pups, plasma cor-
ticosterone was not significantly different from sham animals
at P20 (Table 1). In ADX-CD pups, plasma corticosterone was
significantly lower than in sham animals (Table 1).
After adrenalectomy, pups exhibited a significantly reduced
weight gain in the ADX and ADX-C groups compared with
sham (Table 1). ADX-CD rats gained weight similarly to
sham-operated rats (Table 1). Total kidney mass was signifi-
cantly reduced in ADX and ADX-C rats, but kidney-to-body
weight ratios were not different from sham animals (Table 1).
ADX-CD rats had an increased kidney-to-body weight ratio
compared with ADX-C rats (Table 1).
In ADX pups supplemented with NaCl and in ADX-C pups,
plasma renin concentration was significantly elevated com-
pared with sham and ADX-CD groups (Table 1). Kidney renin
mRNA level was significantly elevated in the ADX group
compared with sham and ADX-CD, whereas, in ADX-C pups,
renin mRNA was not different from sham (Table 3).
Kidneys from the ADX group were smaller and exhibited
medullary injury with dilated pelvis and a small papilla com-
pared with sham and ADX-CD rats (Fig. 1A). Kidneys from the
ADX-CD group were macroscopically indistinguishable from
sham (Fig. 1A). Morphometric assessment showed that kidneys
from ADX pups displayed a significantly reduced papillary
area, a thinner outer medulla, and a significant reduction in
cortical surface-papillary tip (“axis”) length (Fig. 1B and Table 2).
Corticosterone replacement corrected the change in outer me-
dulla thickness and axis length, but not papillary area (Table 2).
ADX-CD kidneys displayed no significant difference of any
measured parameter compared with sham (Table 2). To ad-
dress whether proliferation was affected in the four groups,
PCNA was used as a mitotic marker. Immunostaining of
kidney sections for PCNA at P20 did not reveal any marked
difference in tissue distribution and labeling intensity between
kidneys from the various groups (Fig. 1C). Western blotting on
whole kidney protein showed that PCNA abundance was not
different between ADX and sham rats at P20 (Fig. 1D).
Staining of kidney sections from pups at P20 for apoptosis by
TUNEL reaction showed very few apoptotic cells and cell
bodies per kidney section with no discernible difference be-
tween kidneys from ADX and sham rats (not shown).
Renal COX-2 Expression in Response to Adrenalectomy
In the ADX group, COX-2 mRNA and protein abundances
in kidney cortex-outer medulla fraction were significantly
higher than those shown in sham animals (Fig. 2A). Cortico-
sterone replacement did not decrease kidney COX-2 mRNA or
protein levels compared with ADX animals. For the ADX-CD
Table 2. Dimensions of kidney regions determined in histological sections at P20 in sham, ADX, ADX-C, and ADX-CD rats
Sham ADX ADX-C ADX-CD
Cortex thickness, m 1,06346 99945 97830 1,11889
Outer medulla thickness, m 1,394104 97755* 1,08273 1,043105
Papilla length, m 4,011180 2,855426 3,168226 3,593226
Axis length, m 6,474125 4,854434* 5,222411 5,756401
Papillary area, mm2 5.550.34 2.830.44* 3.730.71* 4.900.35
Values are means  SE; n  5 separate rats in each group. All data sets were normally distributed. *P  0.05 as estimated by ANOVA followed by Dunnet’s
post hoc test where the sham group was control.
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group, renal COX-2 mRNA and protein levels were similar to
those for sham animals (Fig. 2A). Tissue concentration of
PGE2 in cortex-outer medulla tissue from ADX-CD rats was
about four times lower than that shown in ADX pups [20.7 
8.5 pg/mg protein (n  6) vs. 84.7  9.1 pg/mg protein (P 
0.05) (n  6)]. Immunohistochemical labeling of kidney tissue
showed that COX-2 signal was localized predominantly in
cortex in all four experimental groups (Fig. 2B). COX-2 was
not readily detectable in the medulla, and visualization re-
quired amplification. COX-2 was associated with inner med-
ullary interstitial cells (not shown). Labeling of kidney tissue
from ADX rats for COX-2 yielded more intense immunoreac-
tivity and more widely distributed signal than shown for sham
and ADX-CD kidneys (Fig. 2B). Kidney sections from ADX-C
rats also displayed more widely distributed COX-2-immuno-
reactive protein than shown in sham and ADX-CD animals
(Fig. 2B). At high-power magnification, COX-2-positive sig-
nals were associated with the cytoplasm in the majority of loop
of Henle cells in the kidney cortex of ADX rats (Fig. 2B,
bottom). In contrast, COX-2-immunoreactive signal from
ADX-CD rat kidney was more faint and detectable only in a
minority of loop of Henle cells (Fig. 2B, bottom).
Fig. 2. A: cyclooxygenase-2 (COX-2) abundance in rat pup kidneys at P20 at the level of mRNA (left) and protein (right). Pups were sham operated (sham) or
adrenalectomized at postnatal day 10 (P10) and substituted with cholesterol pellets with no steroid (sham and ADX), with 12.5% corticosterone (ADX-C), and
with 12.5% corticosterone and 12.5% DOCA (ADX-CD); n  5 or 6 in each group in the quantitative RT-PCR experiments and n  4 in the Western blotting
experiments. *P  0.05. B, top: micrographs of histological sections of kidneys at P20 in sham or ADX groups at P10 that are reacted with a COX-2-specific
antibody by histochemical reaction. Bars  200 m. B, bottom: high-power micrographs of kidney sections labeled for COX-2 from an ADX rat (left) and
ADX-CD rat (right). Bars  50 m.
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Urinary-Concentrating Ability in Response to Adrenalectomy
In normohydrated pups, there were no significant differences
in urine osmolality between the four experimental groups at
P20 (Table 1). There was a tendency for lower plasma Na
concentration ([Na]) in ADX and ADX-C groups, but this
was not statistically significant; however, plasma [Na] in
ADX-CD rats was significantly elevated compared with that
shown for ADX-C rats (Table 1). In response to fluid depri-
vation, plasma [Na] was significantly lower in ADX-C and
ADX pups than in sham rats (Table 1). In the ADX-CD group,
plasma [Na] was significantly elevated compared with that
shown for all other groups (Table 1). Fluid deprivation in-
creased urine osmolality in sham-operated rats compared with
normohydrated sham-operated pups (Table 1). In ADX and
ADX-C groups, urine-concentrating ability was significantly
lower than that shown for sham rats (Table 1). In response to
fluid deprivation, urine osmolality in ADX and ADX-C rats did
not increase significantly compared with normohydrated coun-
terparts (Table 1). In the ADX-CD group, urinary-concentrat-
ing ability was not different from that shown in sham animals
and significantly higher than that shown in ADX and ADX-C
groups (Table 1). Osmolality and [Na] in papillary tissue
interstitial fluid changed similarly to urine-concentrating abil-
ity; these levels were significantly reduced in ADX and
ADX-C groups compared with sham, whereas levels in
ADX-CD rats were not significantly different from those in
sham animals (Table 1). NaCl transport molecule expression
was determined in cortex-outer medulla tissue fraction. Adre-
nalectomy with or without gluco- and mineralocorticosteroid
substitution did not significantly alter mRNA abundances of
the investigated NaCl transport molecules [NKCC2, ROMK,
Na-K-ATPase 1-subunit, renal Na/H exchanger
(NHE3), and -epithelial Na channel] and 11	-hydroxy-
steroid dehydrogenase-2 as determined by quantitative RT-
PCR (Table 3). Ribonuclease protection assays for NKCC2
and Na-K-ATPase 1-subunit mRNAs corroborated the
results obtained by quantitative RT-PCR (Fig. 3A). Western
blotting experiments showed a lower abundance of Na-K-
ATPase 1-subunit protein in kidney tissue from ADX group
(Fig. 3B), whereas NKCC2 was not changed (not shown).
Immunohistochemical staining for NKCC2 (Fig. 3C) and
ROMK (not shown) confirmed the pathological change with a
thinner outer medulla but did not reveal any appreciable
differences in tissue distribution or labeling intensity of immu-
noreactive proteins. NKCC2 was associated with the loops of
Henle in outer medulla and in cortical medullary rays (Fig.
3C). Labeling intensity was reduced for Na-K-ATPase
1-subunit in ADX rats compared with the other groups
(Fig. 3C). Immunoreactive signal for Na-K-ATPase was as-
sociated with the basolateral aspect of epithelial cells in the dis-
tal convoluted and connecting tubules in cortex and loop of
Henle cells in the outer medulla (Fig. 3C). There were no ob-
vious differences in the distribution pattern and staining inten-
sity between control, ADX-C, and ADX-CD groups (Fig. 3C).
Role of COX-2 for Impaired Concentrating Ability and
Weight Gain in ADX Rats
At P17, ADX rats were divided into two groups: vehicle
(weight: 33.5  0.7 g, mean  SE, n  13) and parecoxib
(weight: 34.1  1 g, n  14). Subcutaneous injection of the
COX-2-selective antagonist parecoxib (5 mg kg1 day1,
P17-P20) enhanced weight gain significantly (Fig. 4A). The
COX-2 inhibitor reduced weight loss after fluid deprivation for
20 h (Fig. 4A). In response to fluid deprivation, plasma osmo-
lality and hematocrit increased significantly less in parecoxib-
treated rats than in vehicle-treated ADX pups (Table 4). Pare-
coxib treatment significantly improved urinary-concentrating
ability and augmented osmolality of papillary interstitial fluid
(Fig. 4, B and C). The increase in osmolality of papillary
interstitial fluid after COX-2 inhibition was achieved through
significantly increased accumulation of Na and urea but not
K (Table 4). The COX-2 inhibitor lowered plasma renin
concentration significantly to a level 1/30 of that in vehicle-
injected fluid-deprived pups (Fig. 4D).
DISCUSSION
The present data show that absence of aldosterone for 10
days before weaning in rat pups leads to renal medullary injury
and impaired urinary-concentrating ability associated with so-
matic growth inhibition and extracellular volume depletion.
The lesions were most prominent in the outer medulla and the
papilla. The injury was elicited late in the postnatal period
(between P10 and P20) despite NaCl supplementation and at a
time when formation of new nephrons has ceased. This post-
natal “window” coincides with intense proliferation of the
loops of Henle (4, 27) and expansion of the renal medulla. The
data indicate that mineralocorticoid supports renal and somatic
growth equally with no detectable effect on renal cell prolif-
eration. In the ADX group, corticosterone was detectable in
plasma (8), but the physiological surge at weaning (P20) was
prevented. Despite the fact that plasma corticosterone was not
significantly elevated in the ADX-C group compared with that
shown in ADX animals 10 days after pellet implantation, the
replacement therapy improved some ADX-induced pathologi-
Table 3. Messenger RNA levels at P20 in the kidneys of rats that were either sham-operated or adrenalectomized at P10
Sham (n9) ADX (n7) ADX-C (n5) ADX-CD (n9)
NKCC-2 2.30.4 3.50.5 2.60.6 2.40.6
ROMK 2.0.3 2.50.3 2.10.4 2.20.4
Na-K-ATPase 1-subunit 4.30.6 5.40.6 4.40.7 4.50.6
NHE3 0.220.04 0.210.03 0.270.05 0.240.04
ENaC 0.980.2 0.960.3 0.810.2 1.10.2
11ßHSD-2 0.700.08 1.020.14 0.760.15 0.760.10
Renin 0.430.06 3.200.12* 2.640.58 0.290.05†
Values are means  SE; n  no. of animals. 11	HSD-2, 11	-hydroxysteroid dehydrogenase-2. Values are starting quantity in ng 
103, and data sets were
normally distributed. NHE3, renal Na/H exchanger; ENaCa, a-endothelial Na channel. Statistical evaluation was performed by ANOVA followed by
Tukey-Kramer multiple comparisons test. P  0.05: *sham vs. ADX and †ADX vs. ADX-CD.
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cal features (survival, thickness of outer medulla). However,
glucocorticoid at plasma levels that are normal in the postnatal
period did not compensate for the lack of mineralocorticoid
judged from reduced somatic growth rate, elevated plasma
renin concentration, decreased urine concentrating ability, and
more marked effect of dehydration on intravascular volume.
This notion is consistent with data that show that betametha-
sone cannot substitute for the lack of aldosterone signaling in
MR knockout mice (1), but it improves urinary-concentrating
ability in rats when administered before weaning (23). Addi-
tion of DOCA to corticosterone pellets normalized weight
gain, led to kidney hypertrophy and hypernatremia, and re-
stored urine-concentrating ability and papillary osmolality in
ADX rats. The ADX and ADX-C groups resemble mouse
models with targeted disruption of aldosterone receptor (MR)
and aldosterone synthase that display severe NaCl wasting,
urinary-concentrating defect, and variable degrees of hydrone-
phrosis despite intact glucocorticoid synthesis (1, 14). The
present study indicates a distinct role of impaired aldoste-
rone signaling for the renal lesions observed after deletion
of upstream renin-angiotensin system components (6, 7, 18,
20, 29, 30).
The observations in the ADX and ADX-C groups that
plasma [Na] is not elevated and does not increase signifi-
cantly after fluid deprivation indicate that rats suffer primarily
from NaCl losses and subsequent water losses. The level of
Na-K-ATPase 1-subunit was lower in the ADX group,
whereas levels of other NaCl transport proteins were not
Fig. 3. A, top: result of ribonuclease protection assays for NKCC2, Na-K-ATPase 1-subunit (NaK-1), and 	-actin. Total RNA from kidneys of sham and
nonsubstituted ADX pups at P20 was used for hybridization with specific radiolabeled probes. A, bottom: quantitative evaluation of the assays; n  5 in each
group. B, top: Western blotting experiment of whole kidney homogenate for Na-K-ATPase 1-subunit from sham, ADX, ADX-C, and ADX-CD rat pups.
B, bottom: densitometric values (OD); n 4 in each group. *P 0.05. C: micrographs of histological sections of kidneys at P20 in sham and ADX groups (ADX,
ADX-C, and ADX-CD) at P10 that are reacted with a NKCC2-specific antibody (top) and an Na-K-ATPase 1-subunit antibody (bottom) by histochemical
reaction. Scale bars  500 m (top) and 50 m (bottom).
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changed (ROMK, NHE3, NKCC2, and epithelial Na channel)
in outer medulla-cortex tissue, consistent with findings in
aldosterone synthase- and MR-deficient mice (1, 14). The data
imply that the effect of corticosteroids on Na transport are not
mediated predominantly at the level of transport protein abun-
dance.
COX-2 activity contributed significantly to the NaCl-wast-
ing phenotype elicited by absence of aldosterone in the post-
natal period. Administration of a COX-2 inhibitor, parecoxib,
increased body weight gain abruptly, which implies an effect
through renal Na handling with subsequent expansion of
extracellular volume. Moreover, in response to fluid depriva-
tion, parecoxib attenuated the increases in hematocrit, plasma
osmolality, plasma [Na], and renin and improved the accu-
mulation of Na and urea in the medullary interstitium. The
improved interstitial hypertonicity achieved by COX-2 inhibi-
tion in the renal medulla is the most likely explanation for the
improved urine-concentrating ability. This effect could be
accomplished by inhibition of prostaglandin effects on the
tubular epithelium and, indirectly, by an improved action of
vasopressin and/or by decreased washout of solutes through a
decrease in medullary perfusion. The primary deficiency in
mineralocorticoid and the negative Na balance augments
renal COX-2 activity, which further enhances renal Na loss.
A similar mechanism is likely to be involved in renal dysfunc-
tion in aldosterone synthase-deficient mice, where intrarenal
COX-2 expression is increased fivefold (14). Concentrating
ability was improved significantly by short-term COX-2 inhi-
bition (Fig. 4) but not reestablished to the level normally
observed at weaning in adrenal-intact rats (2,000 mosmol/
kgH2O). Whether intervention with COX inhibitors beyond 3
days can rescue the medullary phenotype induced by absence
of mineralocorticoid is not resolved by the present experi-
ments. We chose a short period of intervention because COX-2
inhibition or gene deletion from birth by itself causes renal
injury in rodents, primarily in the renal cortex (5, 12, 17).
As noted by Makhanova et al. (14), the medullary injury
after mineralocorticoid deficiency bears a striking resemblance
to the effect of ureteral obstruction during postnatal develop-
Fig. 4. Effect of a COX-2 inhibitor (parecoxib, 5
mg kg1 day1) from P17 to P20 on weight
change, urinary concentration ability, and plasma
renin concentration in ADX rat pups at P10. No.
of animals is shown in each column. A: relative
body weight (BW) gain of ADX rats with and
without COX-2 inhibition from P17 to P20 (left)
and relative body weight loss after fluid depriva-
tion for 20 h between P20 and P21 (right). *P 
0.05. B: effect of a COX-2 inhibitor on urine
osmolality after fluid deprivation of ADX rats for
20 h between P20 and P21. *P  0.05. C: effect
of a COX-2 inhibitor on inner medullary tissue
interstitial osmolality (geometric means) in ADX
rats subjected to fluid deprivation for 20 h be-
tween P20 and P21. *P  0.05. D: effect of a
COX-2 inhibitor on plasma renin concentration
(geometric means) in ADX, fluid-deprived pups
(20 h, P20–P21). *P  0.05.
Table 4. Effect of a COX-2 selective inhibitor parecoxib
(5 mg kg1 day1 from P17 to P20) on plasma parameters
and urinary-concentrating ability in adrenalectomized,
nonsteroid-substituted rats that were fluid deprived
for 20 h
Vehicle Parecoxib (5 mg/kg) P Value
Plasma [Na], mM 1291.2 (13) 133.71.4 (14)* 0.02
Hematocrit 40.91.2 (10) 35.71.2 (9)* 0.02
Plasma osmolality,
mosmol/kgH2O 3244 (13) 3011 (14)* 0.0001
Papillary urea, mM 92.412.6 (12) 178.714.2 (14)* 0.0002
Papillary [Na], mM 58.24.1 (12) 93.15.5 (14)* 0.0001
Papillary [K], mM 78.4 (12) 86.9 (14) 0.3
Values are means  SE, except for papillary [K], which are medians; no.
in parentheses are number of separate rats. All pups were adrenalectomized on
P10 and given NaCl supplementation but no steroid replacement. COX-2,
cyclooxygenase-2. Statistical evaluation was performed by unpaired Student’s
t-test. Papillary [K] data were tested by Mann-Whitney test. *Significant at
P  0.05.
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ment. In accord, administration of angiotensin-converting en-
zyme inhibitors from birth leads to dilatation of tubules in the
rat kidney medulla (13), and deletion of AT1 receptors leads to
increased intrapelvic pressure and impaired peristaltic propa-
gation of urine in mice (16). In the present study, ANG II
signaling was not impaired, but medullary damage was evi-
dent, suggesting a distinct role for aldosterone. The ADX pups
are likely to exhibit polyuria similar to other situations with
impaired renin-angiotensin signaling. This may directly lead to
increased pelvic pressure as suggested to be the case also in
Ren1C-deficient mice, where aldosterone concentration is
strongly decreased (29). Extreme polyuria in the neonatal
period as induced by furosemide or NKCC2 gene deletion
causes more pronounced but basically similar pathological
changes in the medulla (28). Supplementation with isotonic
NaCl after adrenalectomy was necessary for survival of pups in
the present study, but it further augments urine flow rate. The
difference in fluid load presented to the kidney and urinary
tract may explain why hydronephrosis was observed less con-
sistently in kidneys from aldosterone synthase- and Ren1C-
deficient mice (14, 29) compared with the present study and to
NKCC2-deficient mice (28). Thus, to survive mineralocorti-
coid deficiency with a defect in urine-concentrating mecha-
nism, pups must drink a volume that is likely to damage the
kidney.
We conclude that mineralocorticoid is required for normal
postnatal development of the renal medulla. Renal COX-2
activity contributes significantly to NaCl loss, extracellular
volume depletion, and decreased urine-concentrating ability in
postnatal mineralocorticoid deficiency. COX inhibitor admin-
istration seems an attractive approach to reduce renal Na and
water losses in such conditions.
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